What Researchers Did
Researchers reviewed patient records to see if initial combination antifungal treatment improved survival for 106 patients with blood cancers and mucormycosis.
What They Found
Of 106 patients, 44% received single-drug therapy and 56% received combination treatment initially. The study found no significant difference in 6-week mortality between these groups (43% for monotherapy vs. 41% for combination therapy). However, patients who survived were more likely to have localized mucormycosis and to have received hyperbaric oxygen therapy.
What This Means for Canadian Patients
This study suggests that for Canadian patients with blood cancers and mucormycosis, starting with combination antifungal therapy may not improve survival compared to single-drug therapy. The finding that survivors were more likely to receive hyperbaric oxygen therapy highlights its potential role, especially for localized infections.
Canadian Relevance
No direct Canadian connection identified. Mucormycosis is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
This study was a retrospective review of patient records, which means it relied on existing data and could not control all variables as a prospective trial would.